Anti-Diabetic Prescriptions Evaluation for Metformin, Sitagliptin and Gemigliptin among Early Moderate Grade New Type II Diabetes Mellitus Patients in Global Tertiary Care Hospitals: An Analytical Study in Rational Pharmacotherapeutics

Author(s): Moumita Hazra*

Introduction: Diabetes mellitus type II is globally very common, yet neglected. Inhibition of dipeptidyl peptidase–4 by DPP–4 inhibitors enhances hormonal activity of incretins (GLP–1, GIP, GRP), stimulates insulin release and reduces glucagon secretion, thus producing anti-hyperglycaemic activity in type II diabetes mellitus patients.

Objective: Anti-diabetic prescriptions evaluation for metformin, sitagliptin and gemigliptin among early moderate grade new type II diabetes mellitus patients in global tertiary care hospitals: An analytical study in rational pharmacotherapeutics.

Materials and methods: 100 new early moderate grade type II diabetes mellitus patients, were prescribed oral metformin 500 mg once daily, sitagliptin 25 mg once daily or gemigliptin 25 mg once daily for 3 months, in monotherapy, or in combination therapy, or in a mixed regimen of monotherapy and combination therapy. The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug in the prescriptions, were evaluated and analysed.

Results: 100% of the prescriptions contained completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug.

Key Words: Biguanides; Metformin; Dipeptidyl peptidase-4 inhibitors; Sitagliptin; Gemigliptin; Prescriptions evaluation


Full-Text | PDF